Abstract:Background CD4+CD25+Foxp3+ T regulatory (Treg) cells play a key role in peripheral tolerance. Rapamycin was approved by the FDA to preserve renal allografts and to be efficacious in patients with several autoimmune diseases [1]. Objectives To investigate the status of Treg cells in active refractory rheumatoid arthritis (RA) and the effects of rapamycin on patients with RA. Methods Forty-five active refractory RA patients were enrolled. Rapamycin was used at a dose of 0.5 mg every 2 days [the preliminary, open-label clinical trial of rapamycin (Clinical Trials.gov number: ChiCTR-IPR-17010307)]. Clinical improvement and immunological assessments were performed before 1st rapamycin dose and 12 weeks post treatment. Blood samples were obtained from RA patients and 75 healthy volunteers for estimation of CD4+ T cell subsets. Results Two patients dropped out due to non-compliance. As compared to healthy controls (median of Treg cells: 33.32 cell/ul), the absolute counts of circulating Treg cells were significantly decreased in patients with active refractory RA (median: 27.17 cell/ul; P=0.046). While the median ratios of Th17/Treg cells in patients with active refractory RA (median: 0.26) were significantly higher than those of healthy volunteers (median: 0.19; P=0.029). No difference in the absolute counts of circulating Th17 cells and Th1 cells was observed between patients with active refractory RA and healthy subjects. Rapamycin treatment led to clinical improvement with the median post-treatment DAS28-ESR decreasing when compared to baseline (from 4.19 to 3.78) in active refractory RA patients. Sixteen patients (16/43 patients, 37.21%) achieved an EULAR moderate response and 6 patients (6/43 patients, 13.95%) reached good response at week 12. Rapamycin administration resulted in an increase in the absolute counts of Treg cells in active refractory RA patients, from a median of 27.17 cell/ul (at week 0) to 37.57 cell/ul (at week 12) (P=0.041). The ratios of Th17/Treg cells shows a reduction from a median of 0.26 at baseline to 0.20 at week 12, but the difference is not significant (P =0.376). No significant difference was observed in the absolute counts of circulating Th17 and Th1 cells after rapamycin treatment. Interestingly, we observed that Treg cells increased before the complete remission of the disease (DAS28 score <2.6) in patients with active refractory RA. At week 12, the mean dose of prednisone which refractory RA patients were receiving decreased from 11.98 mg/d to 8.31 mg/d, with a dose reduced by ≥30% than that at baseline. The categories of DMARDs use were also reduced (P<0.05). No serious adverse events was observed during the 12-week period of rapamycin treatment. Conclusions Reduced absolute number of Treg cells was found in the patients with active refractory RA, indicating an imbalance between Th17 and Treg cells. Rapamycin elicits rapid improvement of disease activity via restoring circulating Treg cells numbers in patients with active refractory RA. References Perl A. Activation of mTOR (mechanistic target of rapamycin) in rheumatic diseases. Nat Rev Rheumatol. 2016. 12(3): 169–82. Disclosure of Interest None declared

Comparison of regulatory T cells and FoxP3-positive T-cell subsets in the peripheral blood of renal transplant recipients with sirolimus versus cyclosporine: a preliminary study.

Impact of Regulatory T Cells on Innate Immune Cells in a Pre-Sensitized Heart Transplant Model

ABCB1 Haplotype Influences the Sirolimus Dose Requirements in Chinese Renal Transplant Recipients.

Effects of Immunosuppressants on CD+ CD25+ Regulatory T Cells in Human Renal Transplant Recipients

Conversion from cyclosporine to sirolimus in chronic renal allograft dysfunction: a 4-year prospective study.

Influence of Sirolimus-Induced TGF-β Secretion on Mouse Treg Cell Proliferation.

The advantage of Sirolimus in amplifying regulatory B cells and regulatory T cells in liver transplant patients

A Retrospective Study of Conversion from Tacrolimus-Based to Sirolimus-Based Immunosuppression in Orthotopic Liver Transplant Recipients.

Imbalance of Different Types of CD4(+)Foxp3(+) T Cells in Renal Transplant Recipients.

The imbalance between Tregs, Th17 cells and inflammatory cytokines among renal transplant recipients

AB0421 Rapamycin Reduces Disease Activity Through Restoring Regulatory T Cell Numbers in Patients with Active Refractory Rheumatoid Arthritis

[Early Conversion from Calcineurin Inhibitor to Sirolimusto after Renal Transplantation:A Prospective, Open-Label and Non-Randomized Control Study].

Expression and suppressive function of CD39+ regulatory T cells in kidney transplant recipients

Do CD4+Foxp3+ Treg cells correlate with transplant outcomes: A systematic review on recipients of solid organ transplantation

Improved Clinical Outcomes in Chinese Renal Allograft Recipients Receiving Lower Dose Immunosuppressants

Conversion to Sirolimus in Orthotopic Liver Transplant Recipients

Impact of Basiliximab on the Proportion of Regulatory T Cells and Their Subsets Early after Renal Transplantation: a Preliminary Report.

Prospective Observational Study of Sirolimus As Primary Immunosuppression after Renal Transplantation

Comparison of T lymphocyte phenotypes between renal transplant recipients on mycophenolate mofetil regime and azathioprine regime

Absolute of CD4 +CD25 +FOXP3 + regulatory T-cell count rather than its ratio in peripheral blood is related to long-term survival of renal allografts

Reduced Exposure to Calcineurin Inhibitors in Renal Transplantation